Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mateos-Muñoz Beatriz, Buti María, Vázquez Inmaculada Fernández, Conde Marta Hernández, Bernal-Monterde Vanesa, Díaz-Fontenla Fernando, Morillas Rosa María, García-Buey Luisa, Badía Ester, Miquel Mireia, Amador-Navarrete Alberto, Rodríguez-Tajes Sergio, Ramos-Merino Lucía, Madejón Antonio, García-Retortillo Montserrat, Arenas Juan Ignacio, Cabezas Joaquín, Santiago Jesús Manuel González, Fernández-Rodríguez Conrado, Cordero Patricia, Diago Moisés, Mancebo Antonio, Pardo Alberto, Rodríguez Manuel, Hoyas Elena, Moreno Jose Javier, Turnes Juan, Simón Miguel Ángel, Marcos-Fosch Cristina, Calleja Jose Luis, Bañares Rafael, Lens Sabela, Garcia-Samaniego Javier, Crespo Javier, Romero-Gomez Manuel, Gea Francisco, de Santiago Enrique Rodríguez, Moreno Santiago, Albillos Agustin
Аннотация
METHODS: Spanish hospital databases (n = 28) including information regarding adult CHB patients on TDF or ETV for the period February 1st to November 30th 2020 were searched for COVID-19, defined as a positive SARS-CoV-2 polymerase chain reaction, and for severe COVID-19.
RESULTS: Of 4736 patients, 117 had COVID-19 (2.5%), 67 on TDF and 50 on ETV. Compared to patients on TDF, those on ETV showed (p < 0.05) greater rates of obesity, diabetes, ischemic cardiopathy, and hypertension. COVID-19 incidence was similar in both groups (2.3 vs. 2.6%). Compared to TDF, patients on ETV more often (p < 0.01) had severe COVID-19 (36 vs. 6%), required intensive care unit (ICU) (10% vs. 0) or ventilatory support (20 vs. 3%), were hospitalized for longer (10.8 ± 19 vs. 3.1 ± 7 days) or died (10 vs. 1.5%, p = 0.08). In an IPTW propensity score analysis adjusted for age, sex, obesity, comorbidities, and fibrosis stage, TDF was associated with a sixfold reduction in severe COVID-19 risk (adjusted-IPTW-OR 0.17, 95%CI 0.04-0.67, p = 0.01).
CONCLUSION: Compared to ETV, TDF seems to play a protective role in CHB patients with SARS-CoV-2 whereby the risk of severe COVID-19 is lowered.